NAVEOS®’ Commentary on the Proposed 340B Discount Program Omnibus Guidance

Share Article

NAVEOS®, the market leader in government revenue enhancement analytics for hospitals, offers commentary on the proposed 340B Drug Discount Program Omnibus Guidance.

News Image
"HRSA has proposed changes to the 340B Program that materially oversteps their rule-making authority, and would have significantly negative impacts on all 340B providers if implemented as proposed” – Bob Gricius, CEO & Founder of NAVEOS®

On August 28, 2015, the Health Resources and Services Administration (HRSA) published the 340B Drug Discount Program Omnibus Guidance and gave NAVEOS® the opportunity to comment on this proposed guidance. The purpose of the 340B Program is to enable covered entities “to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” (H.R. Rep. No. 102-384(II), at 12 (1992). It is important that any guidance issued, and any enforcement action taken in connection with such guidance, be consistent with this purpose.

Click here to read the full article.


NAVEOS® is a national healthcare data analytics firm headquartered in Virginia focused on maximizing governmental healthcare program reimbursements for hospitals. With its patented technology and domain expertise and processes, NAVEOS® analyzes patient populations to ensure that its hospital clients receive 100% of the governmental reimbursements to which they are entitled. Questions can be directed to NAVEOS® at info(at) or (888)550-2708.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Gricius
+1 (888) 550-2708
Email >
Visit website